{"id":"salmeterol-mdi","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Nervousness"},{"rate":"1-3","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"1-3","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. Its lipophilic properties allow it to partition into airway tissue, providing a depot effect that extends its duration of action to approximately 12 hours, making it suitable for twice-daily dosing in chronic obstructive airway diseases.","oneSentence":"Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:24.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT06655012","phase":"NA","title":"Salmeterol Effect on Exercise Performance","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":36},{"nctId":"NCT06657547","phase":"NA","title":"Urinary Concentration After Salmeterol","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":24},{"nctId":"NCT06654986","phase":"NA","title":"Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-31","conditions":"Healthy","enrollment":36},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Asthma","enrollment":404},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT02232087","phase":"PHASE1","title":"Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2014-07","conditions":"Healthy","enrollment":52},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT00363480","phase":"PHASE4","title":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-17","conditions":"Asthma","enrollment":221},{"nctId":"NCT00214019","phase":"NA","title":"The Effect of Salmeterol on Eosinophil (EOS) Function","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-11","conditions":"Allergic Asthma","enrollment":36},{"nctId":"NCT00315744","phase":"PHASE4","title":"Viapaed Study In Children And Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT02433834","phase":"PHASE2","title":"Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-05-27","conditions":"Asthma","enrollment":248},{"nctId":"NCT02113436","phase":"PHASE4","title":"Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-01","conditions":"Asthma","enrollment":300},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT02416180","phase":"PHASE4","title":"Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-18","conditions":"Asthma","enrollment":111},{"nctId":"NCT00605891","phase":"PHASE2","title":"Dose Finding Study of CHF 4226 for Treating Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":278},{"nctId":"NCT00633217","phase":"PHASE4","title":"Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":247},{"nctId":"NCT00369993","phase":"PHASE2","title":"Spacer Comparison In Adult Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Asthma","enrollment":20},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02415179","phase":"NA","title":"Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-05","conditions":"Asthma","enrollment":52},{"nctId":"NCT01853787","phase":"PHASE4","title":"Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study","status":"COMPLETED","sponsor":"University of Milan","startDate":"2014-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":49},{"nctId":"NCT02466503","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-08","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT00449046","phase":"PHASE3","title":"Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Bronchial Asthma","enrollment":40},{"nctId":"NCT02254226","phase":"PHASE1","title":"Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT02242253","phase":"PHASE2","title":"Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":97},{"nctId":"NCT01332422","phase":"","title":"Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Asthma","enrollment":300},{"nctId":"NCT01172808","phase":"PHASE3","title":"Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Asthma","enrollment":1071},{"nctId":"NCT01172821","phase":"PHASE3","title":"Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Asthma","enrollment":1032},{"nctId":"NCT00535366","phase":"PHASE2","title":"Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":103},{"nctId":"NCT00350207","phase":"PHASE2","title":"Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-07","conditions":"Asthma","enrollment":388},{"nctId":"NCT00563381","phase":"PHASE4","title":"Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":7376},{"nctId":"NCT00239421","phase":"PHASE4","title":"A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":605},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT00685841","phase":"PHASE3","title":"A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-02","conditions":"COPD","enrollment":717},{"nctId":"NCT00404261","phase":"PHASE4","title":"Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01","conditions":"Asthma","enrollment":132},{"nctId":"NCT00064402","phase":"PHASE3","title":"Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-04","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":741},{"nctId":"NCT00064415","phase":"PHASE3","title":"To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-06","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":799},{"nctId":"NCT01089127","phase":"PHASE3","title":"Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":552},{"nctId":"NCT01271556","phase":"NA","title":"Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients","status":"COMPLETED","sponsor":"University of Milan","startDate":"2008-12","conditions":"Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients, Chronic Obstructive Pulmonary Disease, Bronchodilator Agents","enrollment":20},{"nctId":"NCT01255579","phase":"PHASE4","title":"Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":10},{"nctId":"NCT01141465","phase":"","title":"Real-world Effectiveness of Combination Therapy in Asthma","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT00448435","phase":"PHASE3","title":"Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Bronchial Asthma","enrollment":51},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANGER"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"ATROPHY"},{"count":1,"reaction":"DYSSTASIA"},{"count":1,"reaction":"EXCITABILITY"},{"count":1,"reaction":"GUILLAIN-BARRE SYNDROME"},{"count":1,"reaction":"INCONTINENCE"},{"count":1,"reaction":"MOVEMENT DISORDER"},{"count":1,"reaction":"NEUROPATHY PERIPHERAL"},{"count":1,"reaction":"PALATAL OEDEMA"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Serevent"],"phase":"phase_3","status":"active","brandName":"Salmeterol MDI","genericName":"Salmeterol MDI","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}